Xiaofeng Zeng

New Capabilities

Professor at Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences

Many rheumatoid arthritis patients do not get enough relief from biologic drugs, the usual next step after methotrexate. Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib kept 91.8% of those patients at an ACR20 response through 76 weeks.

Updated Oct 31